Clinical trial

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

NCT05746897

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention NM1F Injection Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pembrolizumab injection Normalized identity: pembrolizumab InjectionView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-04-13

PhasePHASE1

Conditions

Ovarian Cancerverified · MONDO: ovarian cancer

Melanomaverified · MONDO: melanoma

Triple Negative Breast Cancercandidate · MONDO: triple-negative breast carcinoma

Colorectal Cancerverified · MONDO: colorectal cancer

Interventions

NM1F InjectionDRUG

Pembrolizumab injectionDRUG · verified · RxNorm: pembrolizumab Injection

Sponsors & collaborators

Hefei TG ImmunoPharma Co., Ltd.lead sponsor

Mapped research locations

DallasTexas, United States1 FairfaxVirginia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05746897 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.